Grant: Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
McGill University
$105,000.00
Elucidating Mechanisms of Resistance to HIV-1 Integrase Inhibitors
FY 2010-11
Summary
HIV-1 encodes three enzymes: reverse transcriptase, protease and integrase, all of which are crucial for viral replication. Until recently, only two of these had been characterized and extensively utilized as therapeutic targets. Although combination therapy against reverse transcriptase and protease can reduce viral burden to levels below the limit of detection, the emergence of mutations in the viral genome can compromise treatment. As a result, the search for new antiretroviral targets has lead to the development of integrase inhibitors. HIV-1 integrase catalyzes the insertion of viral DNA into the host chromosome where it can persist. Raltegravir is a potent, first-generation integrase inhibitor; however, the inhibitor is also vulnerable to the development of resistance. A better understanding of how mutations in the integrase enzyme confer resistance to raltegravir is necessary in order to establish a basis for developing new inhibitors. We have used recent structural data from a related retroviral integrase to analyze with computer-based software how resistance mutations can affect inhibitor binding. We propose to compare the computer-based predictions to data obtained with the purified HIV integrase enzyme. A correlation between the prediction and actual data would validate the structural model. Success in this research would facilitate the development of new integrase inhibitors that are active against both wild-type and resistant mutant viruses.
Department
Program
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
219113
Name
Biondi Mia J
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Elucidating Mechanisms of Resistance to HIV-1 Integrase Inhibitors
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Biomedical/Clinical HIV/AIDS Research
Keyworddelim
Biochemistry; Enzyme Kinetics; Hiv-1; In Silico Studies; Inhibition Studies; Integrase; Pre-Clinical; Protein-Nucleic Acid Interactions; Resistance Mechanisms; Virology
Abstract
HIV-1 encodes three enzymes: reverse transcriptase, protease and integrase, all of which are crucial for viral replication. Until recently, only two of these had been characterized and extensively utilized as therapeutic targets. Although combination therapy against reverse transcriptase and protease can reduce viral burden to levels below the limit of detection, the emergence of mutations in the viral genome can compromise treatment. As a result, the search for new antiretroviral targets has lead to the development of integrase inhibitors. HIV-1 integrase catalyzes the insertion of viral DNA into the host chromosome where it can persist. Raltegravir is a potent, first-generation integrase inhibitor; however, the inhibitor is also vulnerable to the development of resistance. A better understanding of how mutations in the integrase enzyme confer resistance to raltegravir is necessary in order to establish a basis for developing new inhibitors. We have used recent structural data from a related retroviral integrase to analyze with computer-based software how resistance mutations can affect inhibitor binding. We propose to compare the computer-based predictions to data obtained with the purified HIV integrase enzyme. A correlation between the prediction and actual data would validate the structural model. Success in this research would facilitate the development of new integrase inhibitors that are active against both wild-type and resistant mutant viruses.
Competitiondate
201010
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Biondi, Mia J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~